ReviewMolecules (Basel, Switzerland)2011
Like a bolt from the blue: phthalocyanines in biomedical optics.
Review in Molecules (Basel, Switzerland), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed.
- Recent Advances in Zinc(II)-Complexes for Antibacterial Photodynamic Therapy.Chemistry, an Asian journal · 2026Review
- Investigation of the enzyme-inhibitory, antibacterial, and anticancer properties of metal phthalocyanines.Turkish journal of chemistry · 2026Article
- Blackberry-Like Doxorubicin Loaded Hyaluronic Acid/Zinc Phthalocyanine Loaded Mesoporous Silica Nanocomposites for Long-Term Tumor Photodynamic and Chemotherapy Synergistic Therapy.International journal of nanomedicine · 2025Article
- State-of-the-art photodynamic therapy for malignant gliomas: innovations in photosensitizers and combined therapeutic approaches.Exploration of targeted anti-tumor therapy · 2025Review
- Use of Antimicrobial Photodynamic Therapy to Inactivate Multidrug-ResistantPharmaceutics · 2024Article
- Cyanine dyes in the mitochondria-targeting photodynamic and photothermal therapy.Communications chemistry · 2024Review
- DFT Studies of Dimethylaminophenyl-Substituted Phthalocyanine and Its Silver Complexes.Molecules (Basel, Switzerland) · 2024Article
- Graphene Oxide/Cholesterol-Substituted Zinc Phthalocyanine Composites with Enhanced Photodynamic Therapy Properties.Materials (Basel, Switzerland) · 2023Article
- Antimicrobial Photodynamic Therapy againstMicroorganisms · 2023Article
- Cytotoxic Effects of Combinative ZnPcSInternational journal of molecular sciences · 2023Article
- Recent Advances in Green Metallic Nanoparticles for Enhanced Drug Delivery in Photodynamic Therapy: A Therapeutic Approach.International journal of molecular sciences · 2023Review
- Novel albumin-binding photodynamic agent EB-Ppa for targeted fluorescent imaging guided tumour photodynamic therapy.RSC advances · 2023Article
- Trial watch: an update of clinical advances in photodynamic therapy and its immunoadjuvant properties for cancer treatment.Oncoimmunology · 2023Article
- On the remarkable nonlinear optical properties of natural tomato lycopene.Scientific reports · 2022Article
- Cationic Axial Ligand Effects on Sulfur-Substituted Subphthalocyanines.Molecules (Basel, Switzerland) · 2022Article
- Tetra-2,3-Pyrazinoporphyrazines with Externally Appended Pyridine Rings 22 Synthesis, Physicochemical and Photoactivity Studies on In(III) Mono- and Heteropentanuclear Complexes.Molecules (Basel, Switzerland) · 2022Article
- Photodynamic therapy for prostate cancer: Recent advances, challenges and opportunities.Frontiers in oncology · 2022Review
- Targeting Cancer Cell Tight Junctions Enhances PLGA-Based Photothermal Sensitizers' Performance In Vitro and In Vivo.Pharmaceutics · 2021Article
- Application of Asymmetrical Flow Field-Flow Fractionation for Characterizing the Size and Drug Release Kinetics of Theranostic Lipid Nanovesicles.International journal of molecular sciences · 2021Article
- Recent Progress in Phthalocyanine-Polymeric Nanoparticle Delivery Systems for Cancer Photodynamic Therapy.Nanomaterials (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The purpose of this review is to compile preclinical and clinical results on phthalocyanines (Pcs) as photosensitizers (PS) for Photodynamic Therapy (PDT) and contrast agents for fluorescence imaging. Indeed, Pcs are excellent candidates in these fields due to their strong absorbance in the NIR region and high chemical and photo-stability. In particular, this is mostly relevant for their in vivo activation in deeper tissular regions. However, most Pcs present two major limitations, i.e., a strong tendency to aggregate and a low water-solubility. In order to overcome these issues, both chemical tuning and pharmaceutical formulation combined with tumor targeting strategies were applied. These aspects will be developed in this review for the most extensively studied Pcs during the last 25 years, i.e., aluminium-, zinc- and silicon-based Pcs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.